Search results
Earnings call: Zealand Pharma reports solid Q1 results, advances in obesity treatment By...
Investing.com· 8 hours agoIn a recent earnings call, Zealand Pharma (NASDAQ:ZEAL), a biotechnology company focused on the...
FDA greenlights self-collection of vaginal samples for cervical cancer screening
KMBC-TV Kansas City· 7 hours agoTwo health care businesses – biotechnology company Roche and medical technology firm Becton, Dickson...
StockNews.com Lowers Puma Biotechnology (NASDAQ:PBYI) to Hold
ETF DAILY NEWS· 3 days agoSeparately, HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, May 3rd. 7 Stocks to Buy ...
Earnings call: Invivyd optimistic about PEMGARDA's market potential
Investing.com· 4 days agoInvivyd, a biotechnology company, recently held an earnings call to discuss their first-quarter...
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International...
Benzinga· 14 hours agoNKGen Biotech, Inc. NKGN ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic ...
PDS Biotechnology Corp. (NASDAQ:PDSB) Uses Cancer Immunotherapy to Infiltrate and Disable Tumors...
The Wall Street Transcript· 3 days agoPDS Biotechnology is a mid- to late-stage clinical development company working in the area of cancer...
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks via Yahoo Finance· 7 days agoMaking its debut on 06/23/2005, smart beta exchange traded fund Invesco Biotechnology & Genome ETF...
Canaccord cuts Aptose Biosciences shares target, expects lead drug approval delay By Investing.com
Investing.com· 15 hours agoOn Thursday, Canaccord Genuity (TSX:CF) adjusted its price target on Aptose Biosciences...
Fact Check: About That Claim 23andMe Sold Genetic Data to Chinese Government
Snopes via Yahoo News· 2 hours agoThis deal, hailed as "a monumental leap in international genetic research collaboration" by some and...
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Morningstar· 14 hours agoJohnson & Johnson has agreed to buy privately-held biotechnology company Proteologix for an initial $850 million in cash in a deal that bolsters the healthcare giant's dermatology ...